The NANOFOL project proposed to develop a new approach for diagnosis and therapy of chronic inflammatory diseases such as rheumatoid arthritis using folate-based nanobiodevices (FBN).
We aimed to improve current treatments by fulfilling the following objectives:
- Design, development and production of FBN directly targeting effector cells;
- Proof of concept for a FBN targeting activated macrophages in chronic inflammation without affecting bystander cells;
- Development of nanodevices coated with a novel type of bispecific antibodies to specifically target activated macrophages in chronic inflammatory disorders;
- Proof of concept for the delivery of therapeutic agents, such as lipophylic molecules or siRNAs, via FBN to target inflammatory signaling pathways;
- In vitro and in vivo testing of cellular toxicity caused by the novel nanobiodevices in cells other than activated macrophages;
- Design of models that will enable to minimize animal experimentation.
In summary, the NANOFOL project combines expertise in nanotechnologies, biology, chemistry, biotechnology, engineering, medical and pharmaceutical sciences to develop via FBN a new diagnostic/therapy approach for cost efficient treatment of chronic inflammatory diseases with low side effects to constitute a more advantageous solution than current therapies.-based nanobiodevices (FBN).
MedUni Vienna Researcher
The MedUni Vienna is project partner under the leadership of Univ.-Prof. Dipl.-Ing. Dr. Hannes Stockinger / Center for Pathophysiology, Infectiology and Immunology, Institute of Hygiene and Applied Immunology.
Project Coordinator: Assoc. Prof. Artur Cavaco-Paulo, Universität Minho, Portugal.
13 Project Partners.
|Topic||FP7-NMP / FP7 NMP-2008-4.0-1/ Nanosciences, nanotechnologies, materials and new production technologies / Large Scale Collaborative Project|
|Project duration||01.12.2009 - 30.11.2013|
|Funding volume, total||EUR 6 631 807|
|Funding volume, Medical University of Vienna||EUR 601 335.85|